NCT05181189 · Phase 2 · NOT YET RECRUITING
NMDA Enhancement Combined With Omega-3 for Early Dementia
This trial tests whether adding omega-3 fatty acids to DAOIB, an experimental drug that boosts NMDA receptor activity in the brain, improves thinking, daily functioning and quality of life. About 140 people with mild cognitive impairment or mild Alzheimer's take part for 24 weeks. It is a Phase 2 trial, testing whether it works and is safe, not yet proven or approved.
You may qualify if
- Clinical diagnosis of Alzheimer's disease or mild cognitive impairment
- MMSE between 10-26
- CDR 1 or 0.5
You're excluded if
- Hachinski Ischemic Score > 4
- Substance abuse/dependence
- Parkinson disease, epilepsy, dementia with psychotic features
- Major depressive disorder
- Major physical illnesses
- memantine or special omega-3 fatty acids therapy within 3 months before enrollment
- Severe visual or hearing impairment
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-10-22